UBS Group’s Frazier Lifesciences Acquisition Corp Unit FLACU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-773
Closed -$8K – 11817
2022
Q3
$8K Sell
773
-5,110
-87% -$51.5K ﹤0.01% 8821
2022
Q2
$58K Buy
5,883
+4,620
+366% +$45.8K ﹤0.01% 5805
2022
Q1
$12K Buy
1,263
+175
+16% +$1.74K ﹤0.01% 8262
2021
Q4
$11K Buy
1,088
+509
+88% +$5.1K ﹤0.01% 8725
2021
Q3
$6K Buy
579
+294
+103% +$2.95K ﹤0.01% 8490
2021
Q2
$3K Sell
285
-1,714
-86% -$17.4K ﹤0.01% 8886
2021
Q1
$20K Buy
+1,999
New +$21.3K ﹤0.01% 7413

UBS Group's FLACU Position: Q4 2022 in Review

UBS Group sold out of Frazier Lifesciences Acquisition Corp Unit (FLACU) in Q4 2022, closing a stake of 773 shares — an estimated $8K sold.

UBS Group first reported a position in FLACU in Q1 2021 and held it in 7 quarters. The position peaked at $58K in Q2 2022. 0 funds tracked by Wall St. Rank hold FLACU as of Q4 2022.

  • UBS Group reported no remaining Frazier Lifesciences Acquisition Corp Unit position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 773 Frazier Lifesciences Acquisition Corp Unit shares in Q4 2022, an estimated $8K.
  • UBS Group first reported a position in Frazier Lifesciences Acquisition Corp Unit in Q1 2021 and held it in 7 quarters.
  • UBS Group's Frazier Lifesciences Acquisition Corp Unit position peaked at $58K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corp Unit as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.